UMR 7200 CNRS/Université de Strasbourg, MEDALIS Drug Discovery Center, 74 Route du Rhin, 67401 Illkirch, France.
J Chem Inf Model. 2012 Sep 24;52(9):2410-21. doi: 10.1021/ci300196g. Epub 2012 Sep 5.
Selectivity is a key factor in drug development. In this paper, we questioned the Protein Data Bank to better understand the reasons for the promiscuity of bioactive compounds. We assembled a data set of >1000 pairs of three-dimensional structures of complexes between a "drug-like" ligand (as its physicochemical properties overlap that of approved drugs) and two distinct "druggable" protein targets (as their binding sites are likely to accommodate "drug-like" ligands). Studying the similarity between the ligand-binding sites in the different targets revealed that the lack of selectivity of a ligand can be due (i) to the fact that Nature has created the same binding pocket in different proteins, which do not necessarily have otherwise sequence or fold similarity, or (ii) to specific characteristics of the ligand itself. In particular, we demonstrated that many ligands can adapt to different protein environments by changing their conformation, by using different chemical moieties to anchor to different targets, or by adopting unusual extreme binding modes (e.g., only apolar contact between the ligand and the protein, even though polar groups are present on the ligand or at the protein surface). Lastly, we provided new elements in support to the recent studies which suggest that the promiscuity of a ligand might be inferred from its molecular complexity.
选择性是药物开发的关键因素。在本文中,我们通过查询蛋白质数据库,以更好地了解具有生物活性的化合物的混杂性的原因。我们组装了一个数据集,其中包含 >1000 对“类药性”配体(因为其物理化学性质与已批准药物重叠)与两个不同的“可成药”蛋白靶标之间的三维结构复合物。研究不同靶标中配体结合位点之间的相似性表明,配体缺乏选择性可能是由于以下原因:(i)自然界在不同的蛋白质中创造了相同的结合口袋,这些蛋白质不一定具有其他序列或折叠相似性,或者(ii)配体本身的特定特征。特别是,我们证明,许多配体可以通过改变其构象、使用不同的化学部分与不同的靶标结合、或采用不寻常的极端结合模式(例如,配体与蛋白质之间只有非极性接触,尽管配体上或蛋白质表面存在极性基团)来适应不同的蛋白质环境。最后,我们提供了新的元素,以支持最近的研究,这些研究表明,配体的混杂性可以从其分子复杂性推断出来。